AGP Executive Report
Last update: 2 hours agoBiotech & Infection Care: ENA Respiratory won A$2.98M to test its INNA-051 nasal spray in a Phase Ib asthma study starting Q1 2027, aiming to restore antiviral defenses in high-risk patients. Antibiotic Resistance Push: Recce Pharmaceuticals is running Phase 3 trials of its R327 gel for diabetic foot infections in Australia and Indonesia, targeting faster action against multidrug-resistant bacteria. Medical AI for Trauma: Flosonics secured a BARDA development contract (about $15M initial, up to $70M) to extend its FloPatch Doppler ultrasound with AI for detecting internal bleeding in mass-casualty scenarios. Energy & Industry Infrastructure: Essity approved £2.85M for hydrogen-ready upgrades at its North Wales mill, targeting lower gas use and emissions; K-Electric pledged Rs15B to strengthen Karachi industrial power reliability. Semiconductors & Manufacturing: CSIRO opened a $6M Brisbane photonics packaging center to build and test photonic chips locally; 3D Systems and Savannah River National Laboratory signed a CRADA to advance additive manufacturing for energy and national security. Policy & Regulation: The Philippines DOE seeks a 2027 spending plan of P5.58B, with EV funding jumping more than sevenfold; U.S. lawmakers advanced bills to tighten communications and satellite rules. Data Centers & Power Markets: SoftBank-backed SB Energy filed for a U.S. IPO as AI-driven power demand accelerates.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
